Kornimate/medical-research-clean huggingface dataset:
honey & nigella sativa trial against covid-19

Conditions: Coronavirus Infection; Sars-CoV2

Summary: to evaluate the effectiveness of nigella sativa and honey stirred in 250 ml of distilled water 12 hourly till patient becomes asymptomatic or a maximum of 14 days with standard hospital care versus standard hospital care alone with placebo capsule and 250 ml water, in clearing the covid-19 nucleic acid from throat and nasal swab, lowering disease detrimental effects on hrct chest/x-ray and severity of symptoms along with duration of hospital stay till day 14th day of follow up and 30 days mortality (primary outcomes).

this cohort, adaptive, randomized, double armed group, controlled, investigator initiated interventional study is designed to demonstrate the superiority of a combination of black cumin with honey over standard care in sars-cov-2 (covid-19) infected patients who consent to randomization following a new diagnosis in pakistan with an ssc-2 score of \> 5 with positive rt-pcr of covid-19.

Eligibility criteria:
inclusion criteria: * confirmed sars-cov-2 (covid-19) infection by a positive test result with ssc-2 score\> 5 * patients admitted in corona centers exclusion criteria: * participants not giving consent. * pregnant and lactating females. * history of allergy to any drug being administered in this study * severely terminally ill patients * patients on nil per oral

Keywords: sars-cov-2 covid-19 coronavirus honey nigella sativa black cummin herbal medicine
lung hiv microbiome project (michigan site)

Conditions: Healthy Participants; Tobacco Use Disorder; Human Microbiome

Summary: in its original phase, this cohort study recruited subjects who were either hiv-positive or hiv-negative healthy controls, to analyze the community structure of the lung microbiome. original recruitment was planned to occur both at the university of michigan medical center and clinics, and at va ann arbor healthcare system. enrollment for the original cohort is completed, and all current activity of this project is occurring at va ann arbor, where both veteran subjects and non-veteran subjects are eligible to participate. this study is currently recruiting only healthy hiv-negative subjects. participation, described below, involves a research bronchoscopy procedure.

this is a non-interventional cohort study with single time point cross-sectional comparisons and longitudinal analyses, with the primary study aims of: evaluating how the immune deficiency associated with hiv infection influences the lung microbiome and lung function, and evaluating changes in lung microbiota over time. the study also aims to characterize the microbiome of the lower respiratory tract, determine the relationship between the lower respiratory microbiome and the upper respiratory and gastrointestinal tract microbiomes, evaluate the influence of smoking on the microbiome compared with the influence of smoking on pulmonary function and respiratory systems, and to evaluate how pneumocystis infection influences hiv-infected and hiv-uninfected individuals.

Eligibility criteria:
inclusion criteria: * negative hiv testing (by elisa) during initial study visit * no signs of respiratory infection at enrollment, such as: fever; recent change in quantity of quality of sputum; chest pain; recent change in shortness of breath or exertional activity * willing and able to sign the informed consent document * if female of child-bearing potential, negative pregnancy test during initial study visit exclusion criteria: * pregnancy * signs or symptoms of respiratory infection at enrollment * unwilling or unable to sign the informed consent document * unstable heart disease * other systemic disease and unlikely to survive at least 2 years * mental incompetence * participation in another interventional protocol within the last 6 weeks * use of antibiotics for a lung infection within the last 4 weeks * renal failure (creatinine \>3) * child's class c cirrhosis

Keywords: lung
clinical investigation of the selectsecure pacing lead

Conditions: Bradycardia

Summary: people who have a slow heart beat, or whose heart does not beat on its own, may be in need of an electronic device called a pacemaker. a pacemaker is implanted surgically just under the skin in the upper chest area. this device helps the heart beat at a regular rhythm by sending electrical signals (pacing) directly to the heart tissue through flexible wires called leads. the purpose of this study is to demonstrate that the selectsecure (model 3830) lead is safe and effective for both sensing the heart's natural rhythm and pacing the heart when it does not beat on its own. this lead will be studied in both the right atrium and right ventricle. a previously market approved medtronic lead model will serve as a comparison to prove the safety and effectiveness of the selectsecure model.


Eligibility criteria:
inclusion criteria: subjects who are in need of a pacemaker that paces in both the right atrium and ventricle. exclusion criteria: subjects who are in need of an implantable cardioverter defibrillator (icd). subjects who have a mechanical or diseased tricuspid valve (a structure in the heart, located between the right atrium and right ventricle, which allows blood to flow from the atrium to the ventricle). steroid contraindication

Keywords: bradycardia
flywheel exercise for ckd

Conditions: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4

Summary: among veterans, the prevalence of chronic kidney disease (ckd) is reported to be as high as 47.3% and a third higher than the general population. muscle wasting and dysfunction have been identified as primary consequences of ckd. disease-induced reductions in lean tissue adversely affect muscle fatigability. consequently, muscle fatigability may serve as a potential limiting factor that contributes to activity limitations. however, there is a lack of evidence informing our understanding of muscle fatigability in patients with ckd. dialysis treatment is a major factor contributing to the high financial costs of ckd care. thus, in addition to potential health and quality of life benefits, treatments capable of maintaining kidney function or delaying the onset of dialysis treatment would provide substantial socio-economic benefit. both lean body mass and muscle fatigability may be improved through strength training. eccentric-overload (i.e. muscle lengthening) progressive resistance exercise (pre) has been shown to be safe and effective for a variety of chronic conditions. eccentric pre using portable flywheel technology may provide a clinically viable treatment option to combat muscle impairments in ckd given the cost effectiveness and minimal space requirements for this mode of exercise. the purpose of this study is to assess feasibility of the eccentric-overload pre regimen for veterans with ckd stage 3 \& 4 predialysis using a prospective single-arm pre-test post-test intervention design. the primary aim of the project is to determine the effects of eccentric-overload pre on muscle fatigability in veterans with ckd stages 3 \& 4 predialysis. feasibility of the regimen will be determined by the time needed to complete the 4-exercise regimen and the perceived exertion levels reported by the study participants.


Eligibility criteria:
inclusion criteria: * ambulatory patients (with or without a gait aid) * ckd stage 3 or 4 * patients receiving care at the dc vamc renal service * the ability to speak and read english * orientation to person, place, and time exclusion criteria: * unable to speak english * acute renal failure * pregnant * unable to follow study instructions * any uncontrolled cardiovascular or musculoskeletal problems that would make participation in this study unsafe

Keywords: resistance exercise muscle fatigue physical function
reliability and validity of the figure of 8 walk test with and without dual-task

Conditions: Stroke

Summary: for people with stroke, walking on a curved path is more difficult than walking on a straight path and can lead to falls. most of the outcome scales assessing the gait of people with stroke involve walking in a straight line or with one turn. assessing a person with stroke walking on a straight path may not be indicative of real-life gait-related performance. the figure of 8 walk test (f8wt) includes a straight and curved gait that may represent the daily gait. to the best of our knowledge, there are no studies evaluating the reliability and validity of the dual-task f8w test in individuals with stroke. therefore, the aim of this study was to evaluate the validity and reliability of the f8w and dual-task f8w test in individuals with stroke.

for people with stroke, walking on a curved path is more difficult than walking on a straight path and can lead to falls. most of the outcome scales assessing the gait of people with stroke involve walking in a straight line or with one turn. assessing a person with stroke walking on a straight path may not be indicative of real-life gait-related performance. the figure of 8 walk test (f8wt) includes a straight and curved gait that may represent the daily gait. to the best of our knowledge, there are no studies evaluating the reliability and validity of the dual-task f8w test in individuals with stroke. therefore, the aim of this study was to evaluate the validity and reliability of the f8w and dual-task f8w test in individuals with stroke. this prospectively designed study evaluated the demographic and clinical characteristics of the participants. the main outcome measures included the f8wt, dual-task f8wt, standardised mini mental test, the national institutes of health stroke scale, timed-up and go test, 10-metre walk test, modified four square step test and six-spot step test.

Eligibility criteria:
inclusion criteria: * 50 years of age or older, * having had only one unilateral stroke at least 6 months before the study, * being medically stable, * being able to walk at least 10 metres with a cane or independently, * getting at least 24 points from the standardised mini mental test, * being able to perform the cognitive task (subtraction) given during the assessments. exclusion criteria: * presence of additional orthopaedic, neurological or cardiovascular diseases that may affect balance and walking, * uncorrectable visual and hearing problems

Keywords: stroke validity and reliability
dexamethasone use in pediatric rhabdomyolysis patients in addition to standard protocols

Conditions: Rhabdomyolysis

Summary: there is a significant unmet need for optimized treatment in rhabdomyolysis. there are few prospective interventional studies on treatment for rhabdomyolysis, a condition which affects diverse and underrepresented populations at a higher rate. while steroids are often used off-label, a systematic study has not yet been initiated, and steroids have not been yet considered in as a consideration to standard care guidelines. the hypothesis is that patients who receive dexamethasone in addition to standard care versus placebo and standard care will have improvement in pain, length of hospital stay, and decrease in kidney complications.

study objective: this is a single center, 2-year, blinded prospective randomized study for those diagnosed with rhabdomyolysis age six months-25 years using dexamethasone versus placebo treatment in addition to standard care in up to 50 patients. study design: patients will be enrolled with a 2:1 ratio of treatment of dexamethasone for 5 days versus placebo treatment for 5 days in addition to receiving standard care. the treatment period for each subject will be five days treatment with oral treatment once per day with study drug (dexamethasone versus placebo). all patients will also receive standard care. patients and their parent/ caregiver will have the option to complete surveys before and after treatment in order to assess pain level and treatment improvement. chart review will be performed on all patients throughout and after the five-day study treatment period. there will be no additional interventions.

Eligibility criteria:
inclusion criteria 1. diagnosis of rhabdomyolysis defined as creatine kinase\> 5000 with trauma excluded 2. ability of parents/patients to understand and the willingness to sign a written informed consent document. 3. patients ages 12 and older will sign written assent exclusion criteria: * already taking systemic steroids. * inability to comply with study instructions. * uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements. * pregnant women. o a urine pregnancy test will be performed for women of child-bearing potential. * below gestational age of 40 weeks * allergy to fluconazole, clotrimazole or nystatin. * cannot tolerate po medications
efficacy and safety study of subcutaneous secukinumab in treatment of subjects with moderate to severe chronic plaque-type psoriasis as compared to etanercept and placebo.

Conditions: Psoriasis

Summary: this withdrawn study was to assess the safety and efficacy of secukinumab compared to etanercept and placebo in patients who have moderate to severe, chronic, plaque-type psoriasis.


Eligibility criteria:
inclusion criteria: * chronic plaque-type psoriasis, moderate to severe * candidate for systemic therapy defined as having psoriasis not adequately controlled by: topical treatment, phototherapy and/or previous systemic therapy exclusion criteria: * forms of psoriasis other than chronic plaque-type * ongoing use of treatments not allowed for psoriasis other protocol-defined inclusion/exclusion criteria may apply
effect of an exercise program of the scapular muscle stabilizers in amateur kayakers shoulder pain

Conditions: Shoulder Pain

Summary: the purpose of this study is to determine whether a specific strengthening program for the stabilizing scapular muscle can reduce shoulder pain of amateur kayaker.


Eligibility criteria:
inclusion criteria: * there have been practicing kayaking over 3 years. * there have been shoulder pain during sports at least 1 month of evolution exclusion criteria: * shoulder pain was caused by a traumatic injury. * to be in medical, pharmacological or shoulder physiotherapy treatment during the study. * to have been surgically intervened in the shoulder

Keywords: strength training scapular stabilization kayakers.
follow up patients with thoracolumbar spondylodiscitis surgically treated by posterior approach

Conditions: Spondylodiscitis

Summary: to evaluate the long term outcomes of patients with thoracolumbar spondylodiscitis treated surgically by posterior approach. outcomes include bony fusion, neurological improvement, pain improvement, implant related complication, recurrence of infection and or reoperation rate

spondylodiscitis is characterized by infection that primarily affects the intervertebral disc and adjacent vertebrae. the estimated incidence of spondylodiscitis, ranging from 0.2 to 10 per 100,000 inhabitants per year, has increased in recent years, which is likely associated with an aging population, higher prevalence of chronic disease, and more effective diagnostic techniques. spondylodiscitis is a life-threatening disease with a mortality rate of 2-20% that is often associated with potential complications, such as paraspinal abscess, epidural abscess, meningitis, spinal instability, and neurologic deficiency. the relapse rates were reported to be as high as 32% in the literature. the aims of this study are to evaluate improvements, complications, recurrence and reoperation rates in assiut university hospitals.

Eligibility criteria:
inclusion criteria: * • all patients had thoracolumbar spondylodiscitis from number 1 thoracic vertebra till number 1 sacral vertebra. * treated surgically by posterior approach only. exclusion criteria: * • patients with incomplete follow up. * multifocal discitis.

Keywords: discitis spondylitis spine surgery
effect of a higher blood-pressure on right ventricular function

Conditions: Blood Pressure; Right Ventricular Dysfunction

Summary: right ventricular (rv) dysfunction in cardiac surgery is an independent risk factor for morbidity and mortality. raising the systemic blood pressure with norepinephrine seems to have a positive influence on the right ventricular function in several animal studies. the current study is designed to evaluate the effect of a higher blood pressure on the rv function in post cardiac surgery patients.

goal: to demonstrate differences in rv function by raising the systemic blood pressure with norepinephrine. study design: randomized controlled trial study population: 78 postoperative cardiac surgery patients admitted at the icu. intervention: * group 1: (n=22): rvef\<20% and map≤65mmhg. intervention with norepinephrine to reach a map of 85mmhg for a maximum duration of two hours. * group 2: (n=22): rvef \<20% and map≤65mmhg. control group: treatment according to current standards. hypotensive patients are treated with fluids and/or vasopressors to gain a mean arterial pressure (map) of 65mmhg. * group 3: (n=17): rvef between ≥20 and \<30% and map ≤65mmhg. intervention with norepinephrine to reach a map of 85mmhg for a maximum duration of two hours. * group 4: (n=17): rvef between ≥20 and \<30% and map ≤65mmhg. control group: treatment according to current standards. hypotensive patients are treated with fluids and/or vasopressors to gain a mean arterial pressure (map) of 65mmhg. endpoints: primary endpoint is the difference between the intervention and the control group in the change over time between baseline and the end of the study period (t4) in rvef. secondary endpoints are the echocardiographic parameters of rv and lv contractility, rv end-diastolic pressure, cardiac index, and fluid balance.

Eligibility criteria:
inclusion criteria: * post operative cardiac surgery patients, full sternotomy * admission at icu * informed consent * right ventricular monitoring by pulmonary artery catheter. * rvef \<30% + map ≤ 65mmhg exclusion criteria: * no informed consent * acute surgery * off pump cardiac surgery * severe tricuspid insufficiency * allergy to norepinephrine * severe left ventricular hypertrophy with systolic anterior movement * chronic use of alpha-blockers * irregulair heart rhythm * surgical reasons to maintain a low blood pressure.
ai in respiratory disease prevention, diagnosis, and triage

Conditions: Respiratory Diseases; Artificial Intelligence (AI); Randomized Controlled Trial

Summary: this study will evaluate the impact of using the gpt-4o compared to traditional online tools in the field of respiratory disease prevention, focusing on the dissemination of knowledge and behavior changes among the general public. we will explore the effectiveness of gpt-4o in enhancing public awareness and management capabilities regarding respiratory diseases and promoting appropriate preventive behaviors.

artificial intelligence (ai) technologies, particularly advanced large language models like gpt-4o developed by openai, hold immense potential in enhancing public health education and preventive behaviors. although gpt-4o was not specifically designed for respiratory disease prevention, it has shown promising prospects in numerous healthcare-related applications, such as providing health information, responding to public inquiries, and supporting health education efforts. however, its effectiveness in improving public awareness and management capabilities regarding respiratory diseases remains to be further explored. understanding and managing respiratory diseases involve complex processes, including symptom recognition, application of preventive knowledge, and informed decision-making. integrating ai tools like gpt-4o into public health education could potentially enhance knowledge dissemination, reduce misinformation, and encourage appropriate preventive behaviors among the general population. nevertheless, gpt-4o has not been specifically validated for respiratory disease prevention and carries the risk of generating misleading or inaccurate information, which could confuse users. improper use of such tools may fail to raise awareness and could even lead to counterproductive behaviors. therefore, studying how large language models like gpt-4o can effectively support public education and behavior change in this context is of critical importance. in this study, participants will be randomly divided into two groups: one group will have access to fine-turned gpt-4o, while the other will rely solely on traditional online tools. they will be presented with scenarios related to respiratory diseases and asked to explain their identification of high-risk factors, understanding of diagnoses, and proposed triage actions for each scenario. each scenario was developed by a panel of three experts in respiratory health, who also established standardized answers. responses will be evaluated by two independent groups of reviewers unaware of the participants' group assignments. these experts independently created initial scoring criteria and resolved discrepancies through multiple rounds of discussion to ensure consistency and accuracy.

Eligibility criteria:
inclusion criteria: * no medical background * aged from 18 to 75 years old exclusion criteria: * had a medical background * exceeds the age criteria * failed to comply with the survey requirements
safety and tolerability of rgb-286638 in patients with selected, relapsed or refractory hematological malignancies

Conditions: Hematological Malignancies

Summary: the purpose of the study is to determine the safety and tolerability of rgb-286638, a novel, multi-targeted kinase inhibitor, administered to patients with selected, relapsed or refractory hematological malignancies.


Eligibility criteria:
inclusion criteria: * histologically/cytologically confirmed diagnosis of: * multiple myeloma (mm) * chronic lymphocytic leukemia (cll) / small lymphocytic lymphoma (sll) * mantle cell lymphoma (mcl) * chronic myelogenous leukemia (cml) * refractory to/relapsed after and/or intolerant of one or more standard therapies or for which no standard therapy exists. * ecog performance status 0-2. * adequate bone marrow, cardiovascular, renal and hepatic function * recovery from all adverse events due to prior therapies * contraception exclusion criteria: * prior chemotherapy, monoclonal antibodies, investigational agents, or radiation therapy (involving ≥ 30% of the active bone marrow) within 14 days prior to the first dose (note nitrosoureas and mitomycin are not permitted for at least 42 days before the first dose of rgb-286638). * cns involvement of the hematological malignancy. * active or unstable cardiac disease and/or history of myocardial infarction within 6 months and/or history of clinically significant ventricular arrhythmias. * concomitant therapies that are known to prolong the qt interval and are associated with a risk of torsades de pointes (tdp) are not permitted within 7 days before the first dose; however, amiodarone is not permitted within 90 days before the first dose. * patients with uncontrolled and unstable intercurrent illness. * concomitant therapy with inhibitors and/or inducers of cyp450 3a4 within 1 week of the first dose. * bleeding disorder unrelated to hematological malignant disease. * hiv or hiv-related malignancy. * history of other malignancies except: (i) adequately treated basal or squamous cell carcinoma of the skin; (ii) curatively treated, a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (iii) other curatively treated solid tumor with no evidence of disease for ≥ 2 years. * any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Keywords: rgb-286638 hematological malignancies